Key result
The β-Tako trial is a randomized, open-label study designed to evaluate the efficacy of beta-blockers on wall motion score index at 7 days in 200 patients with Tako-tsubo syndrome.
Why the study?
Treatment for tako-tsubo syndrome remains empirical, with most patients receiving beta-blockers despite unknown etiology and a lack of randomized trial evidence.
Do beta-blockers improve wall motion score index at 7 days in patients with Tako-tsubo syndrome?
RCT (n=200)
Open-label
1:1
Yes
Do beta-blockers improve wall motion score index at 7 days in patients with Tako-tsubo syndrome?
The β-Tako trial is designed to provide robust scientific evidence on the efficacy and safety of beta-blockers in Tako-tsubo syndrome, addressing a major gap in empirical treatment.
Beta-blocker discharge therapy was associated with fewer MACE and lower mortality in TTS; leaves open need for RCTs to confirm net benefit.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Alfonso et al. (2024) conducted an RCT in Tako-tsubo syndrome (n=200). Beta-blockers vs. No beta-blockers was evaluated on Wall motion score index by echocardiography at 7 days. The β-Tako trial is a randomized, open-label study designed to evaluate the efficacy of beta-blockers on wall motion score index at 7 days in 200 patients with Tako-tsubo syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: